827 reports of this reaction
2.7% of all ZIPRASIDONE MESYLATE reports
#4 most reported adverse reaction
TYPE 2 DIABETES MELLITUS is the #4 most commonly reported adverse reaction for ZIPRASIDONE MESYLATE, manufactured by ROERIG. There are 827 FDA adverse event reports linking ZIPRASIDONE MESYLATE to TYPE 2 DIABETES MELLITUS. This represents approximately 2.7% of all 30,183 adverse event reports for this drug.
Patients taking ZIPRASIDONE MESYLATE who experience type 2 diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TYPE 2 DIABETES MELLITUS is a less commonly reported adverse event for ZIPRASIDONE MESYLATE, but still significant enough to appear in the safety profile.
In addition to type 2 diabetes mellitus, the following adverse reactions have been reported for ZIPRASIDONE MESYLATE:
The following drugs have also been linked to type 2 diabetes mellitus in FDA adverse event reports:
TYPE 2 DIABETES MELLITUS has been reported as an adverse event in 827 FDA reports for ZIPRASIDONE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TYPE 2 DIABETES MELLITUS accounts for approximately 2.7% of all adverse event reports for ZIPRASIDONE MESYLATE, making it a notable side effect.
If you experience type 2 diabetes mellitus while taking ZIPRASIDONE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.